MindRank Partners with 3SBio to Commercialize its AI-Designed Oral GLP-1 in China

Cite

APA MLA Chicago

MindRank Partners with 3SBio to Commercialize its AI-Designed Oral GLP-1 in China. (2026, September 28). Toronto Star. https://www.thestar.com/globenewswire/mindrank-partners-with-3sbio-to-commercialize-its-ai-designed-oral-glp-1-in-china/article_c2934f4b-6334-5eae-a75d-43df125c54f2.html

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

Toronto Star · collected 2026-09-28 · by GlobeNewswire, Inc.

Quick Summary

MindRank AI Ltd., based in Hangzhou, has partnered with subsidiaries of 3SBio Inc. to commercialize MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist for obesity and overweight treatment. The deal covers China, Hong Kong, and Macau and could be worth up to RMB 1.75 billion (USD 260 million).

Written by AI on 2026-09-28, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

MindRank AI Ltd., a company based in Hangzhou, China, has signed a strategic commercialization agreement with two subsidiaries of 3SBio Inc.: Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. and Zhejiang Wansheng Pharmaceutical Co., Ltd. The agreement is for the development and sale of MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist currently in a pivotal Phase 3 trial in China to treat obesity and overweight conditions. This collaboration will cover mainland China, Hong Kong, and Macau, with a total potential transaction value of up to RMB 1.75 billion (USD 260 million).

Written for “AI Drug Development Partnership China” on 2026-10-31, grounded in this article and the 0 other(s) covering the same event.

Story

📰 AI Drug Development Partnership China

Technology · 1 article(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted

sentences that state something as happening or true

Uncertain

0 of 2 hedged ("reportedly", "may", "according to")

Leaning

not political

takes no side on a contested political question

Publisher signals

64/100

Toronto Star's corrections and hedging, across everything collected from it. Not a measure of accuracy.

Outlets on this story

Technology

Same framing elsewhere

articles that frame the event the way this one does

Analyzed 2026-09-28 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability

Source leaning vs. consistency

Publisher

Toronto Star · 10661 article(s) · 27 correction(s) detected

Running correction rate · 27 correction(s)

2026-10-26

Correction

2026-10-24

Correction

2026-10-22

News Clarification for Oct. 22

2026-10-21

No. 6 Hoosiers try to for rare rebound at Michigan after turning the page on 22-game winning streak

2026-10-19

Driver’s License Suspensions for Court Debt Draw Scrutiny

2026-10-16

Amputations and cancer treatment delays: Lawmakers hear testimony on Mississippi prison healthcare

2026-10-16

UPDATE: Golconda Gold Releases Q3 2026 Production Update at Galaxy

2026-10-08

News Clarification for Oct. 8

2026-10-07

Correction

2026-10-05

Entertainment Correction for Oct. 5

2026-10-03

Tennessee's prisons chief is resigning after failed execution of Christa Pike

2026-09-28

Organizations call for Action to End the Deaths of Indigenous People in Custody

2026-09-27

Police memorial recognizes six officers killed in the line of duty in 2026

2026-09-27

UPDATE: WSP to host Power & Energy-focused investor event virtually only

2026-09-26

News Clarification for Sept. 27

2026-09-26

Former federal public servant seeks better pensions for injured workers

2026-09-25

News Corrections for Sept. 25

2026-09-25

She has not been charged. But the Project South allegations have branded her with a 'scarlet letter'

2026-09-24

Correction

2026-09-23

MULTIMEDIA UPDATE: Smith+Nephew launches the new EVOS™ PELVIC Plating System at the 2026 Orthopedic Trauma Association (OTA) Annual Meeting, expanding the EVOS Plating Platform for pelvic and acetabular fracture management

2026-09-22

Costa Rican man complained of lack of care for diabetes before his death in ICE custody, family says

2026-09-22

Judges' grilling of accused men leads to sex assault and dangerous driving cases being overturned

2026-09-20

Jura Energy Corporation Provides Clarification Regarding Media Reports Concerning Its Petroleum Rights in Pakistan

2026-09-19

New details emerge about Toronto's guns-for-hire and the 'crash-out mission" that sparked the Project South investigation

2026-09-17

UPDATE: Osisko Critical Minerals Corporation Announces C$100 Million Private Placement of Special Warrants

2026-09-17

Alabama set to execute man for pawn shop killings months after his nitrogen gas execution blocked

2026-09-04

Orca Corrects Q3 Quarterly Dividend Announcement

Who wrote this

No reporter is named on this article, beyond the feed's “GlobeNewswire, Inc.”.

Topics

China HANGZHOU MindRank MindRank AI Ltd. Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd.

Subjects

China GPE · 3× 01530.HK ORG · 1× 3SBio Inc. ORG · 1× HANGZHOU GPE · 1× Mandi ORG · 1× MindRank ORG · 1× MindRank AI Ltd. ORG · 1× Wansheng ORG · 1× Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. ORG · 1× Zhejiang Wansheng Pharmaceutical Co., Ltd. ORG · 1×

Narrative

MindRank AI Ltd. (“MindRank”) today announced that it has entered into a strategic commercialization agreement with Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd. (“Mandi”) and Zhejiang Wansheng Pharmaceutical Co., Ltd. (“Wansheng”), both subsidiaries of 3SBio Inc. (01530.HK) group, for MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist in a pivotal Phase 3 trial in China for obesity and overweight.

framing: assertive · carried by 1 article(s) · first seen 2026-09-28

2026-09-28 · Toronto Star

MindRank Partners with 3SBio to Commercialize its AI-Designed Oral GLP-1 in China · assertive framing

Claims (2 extracted, 0 hedged)

it → announce → obesity

The collaboration covers mainland China, Hong Kong and Macau, with a total potential transaction value of up to RMB 1.75 billion (USD 260 million). asserted

collaboration → cover → billion

💬Give feedback

🕘History 🎫Support

Terms · Privacy · beta v2.0.0

Articles to 31 Oct 2026